News
SESN
0.6288
0.00%
0.00
Based on the provided financial report articles, the title of the article is: "Carisma Therapeutics Inc. (Form 10-K)
Press release · 04/07 12:05
Carisma Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03/31 23:04
CARISMA THERAPEUTICS INC: HAS PAUSED ALL RESEARCH AND DEVELOPMENT ACTIVITIES AT THIS TIME, PENDING OUTCOME OF REVIEW
Reuters · 03/31 20:30
CARISMA THERAPEUTICS INC: ON DEC 24, APPOINTS NATALIE MCANDREW AS PRINCIPAL FINANCIAL OFFICER
Reuters · 12/26/2024 21:04
CARISMA THERAPEUTICS INC <CARM.O>: BAIRD CUTS TO NEUTRAL RATING; CUTS TARGET PRICE TO $1 FROM $10
Reuters · 12/12/2024 06:13
CARISMA THERAPEUTICS INC <CARM.O>: BTIG CUTS TO NEUTRAL FROM BUY
Reuters · 12/10/2024 08:31
CARISMA THERAPEUTICS INC - CHIEF FINANCIAL OFFICER, RICHARD MORRIS WILL LEAVE COMPANY EFFECTIVE DEC 31
Reuters · 12/09/2024 13:30
CARISMA THERAPEUTICS, INC. <CARM.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $5 FROM $8
Reuters · 11/25/2024 11:12
U.S. RESEARCH ROUNDUP-Domino's Pizza, Elastic NV, Snowflake
Reuters · 11/25/2024 07:05
CARISMA UNVEILS PROMISING PRE-CLINICAL DATA ON ANTI-GPC3 IN VIVO CAR-M THERAPY FOR HEPATOCELLULAR CARCINOMA
Reuters · 11/08/2024 12:30
CARISMA -ANTI-GPC3 IN VIVO CAR-M THERAPY WELL TOLERATED IN MOUSE MODELS, HIGHLIGHTING ITS POTENTIAL AS AN OFF--SHELF TREATMENT FOR GPC3+ SOLID TUMORS
Reuters · 11/08/2024 12:30
Carisma Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/07/2024 15:10
CARISMA THERAPEUTICS INC: CASH & CASH EQUIVALENTS OF $26.9 MILLION EXPECTED TO FUND CO INTO Q3 OF 2025
Reuters · 11/07/2024 12:30
CARISMA THERAPEUTICS Q3 OPERATING EXPENSES USD 16.529 MILLION
Reuters · 11/07/2024 12:30
CARISMA THERAPEUTICS INC: GOT NOTICE OF FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM NASDAQ
Reuters · 10/11/2024 20:51
CARISMA THERAPEUTICS Q2 NET INCOME USD -11.162 MILLION
Reuters · 08/08/2024 11:30
CARISMA THERAPEUTICS ANNOUNCES EXPANSION OF ITS SCIENTIFIC ADVISORY BOARD
Reuters · 08/06/2024 11:30
More
Webull provides a variety of real-time SESN stock news. You can receive the latest news about Sesen Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SESN
More
Carisma Therapeutics Inc., formerly Sesen Bio, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The Company's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.
Recently
Symbol
Price
%Change